Schering AG, Germany, Announces European Approval of Radioimmunotherapy Zevalin®
Schering AG, Germany, Announces European Approval of Radioimmunotherapy Zevalin® Media Alert Zevalin® combines the targeting ability of an anti-CD20 monoclonal antibody with the cytotoxic power of beta radiation emitted by the yttrium-90 isotope (Ytracis®) - a pure beta emitter radiopharmaceutical - to effectively destroy lymphoma cells. Radioimmunotherapy with Zevalin® has been shown to be effective in patients who were refractory to antibody treatment thus offering a new prospect for improving the quality of life for these patients. What: Journalists are invited to access live webcast to